Imgatuzumab

Imgatuzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from rat)
Target	EGFR
Clinical data
ATC code	none;
Identifiers
CAS Number	959963-46-3;
ChemSpider	none;
UNII	V77J4WJF9Z;
KEGG	D10439;
Chemical and physical data
Formula	C6434H9942N1718O2016S44
Molar mass	145028.96 g·mol−1

Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody^[1] that acts as an immunomodulator.^[2]^[3]

The drug was developed by Genentech/Roche.

References

^ Kol A, Terwisscha van Scheltinga A, Pool M, Gerdes C, de Vries E, de Jong S (July 2017). "ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells". Oncotarget. 8 (28): 45432–45446. doi:10.18632/oncotarget.17139. PMC 5542198. PMID 28467975.
^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Imgatuzumab, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[pmid28467975-1] Kol A, Terwisscha van Scheltinga A, Pool M, Gerdes C, de Vries E, de Jong S (July 2017). "ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells". Oncotarget. 8 (28): 45432–45446. doi:10.18632/oncotarget.17139. PMC 5542198. PMID 28467975.

[2] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

[3] Statement On A Nonproprietary Name Adopted By The USAN Council - Imgatuzumab, American Medical Association.

[1]